{"markup":"\u003C?xml version=\u00221.0\u0022 encoding=\u0022UTF-8\u0022 ?\u003E\n    \u003Chtml version=\u0022HTML+RDFa+MathML 1.1\u0022\n    xmlns:content=\u0022http:\/\/purl.org\/rss\/1.0\/modules\/content\/\u0022\n    xmlns:dc=\u0022http:\/\/purl.org\/dc\/terms\/\u0022\n    xmlns:foaf=\u0022http:\/\/xmlns.com\/foaf\/0.1\/\u0022\n    xmlns:og=\u0022http:\/\/ogp.me\/ns#\u0022\n    xmlns:rdfs=\u0022http:\/\/www.w3.org\/2000\/01\/rdf-schema#\u0022\n    xmlns:sioc=\u0022http:\/\/rdfs.org\/sioc\/ns#\u0022\n    xmlns:sioct=\u0022http:\/\/rdfs.org\/sioc\/types#\u0022\n    xmlns:skos=\u0022http:\/\/www.w3.org\/2004\/02\/skos\/core#\u0022\n    xmlns:xsd=\u0022http:\/\/www.w3.org\/2001\/XMLSchema#\u0022\n    xmlns:mml=\u0022http:\/\/www.w3.org\/1998\/Math\/MathML\u0022\u003E\n  \u003Chead\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_itu2PgFdrjV-docKmLK8Jn5oXe_05RgvQh73eOhI_mE.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_at_symbol.js?nzlj21\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_article_reference_popup.js?nzlj21\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_I8yX6RYPZb7AtMcDUA3QKDZqVkvEn35ED11_1i7vVpc.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\n(function(i,s,o,g,r,a,m){i[\u0022GoogleAnalyticsObject\u0022]=r;i[r]=i[r]||function(){(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)})(window,document,\u0022script\u0022,\u0022\/\/www.google-analytics.com\/analytics.js\u0022,\u0022ga\u0022);ga(\u0022create\u0022, \u0022UA-15605596-27\u0022, {\u0022cookieDomain\u0022:\u0022auto\u0022});ga(\u0022set\u0022, \u0022page\u0022, location.pathname + location.search + location.hash);ga(\u0022send\u0022, \u0022pageview\u0022);ga(\u0027create\u0027, \u0027UA-189672-26\u0027, \u0027auto\u0027, {\u0027name\u0027: \u0027hwTracker\u0027});\r\nga(\u0027hwTracker.send\u0027, \u0027pageview\u0027);\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\njQuery.extend(Drupal.settings, {\u0022basePath\u0022:\u0022\\\/\u0022,\u0022pathPrefix\u0022:\u0022\u0022,\u0022highwire\u0022:{\u0022markup\u0022:[{\u0022requested\u0022:\u0022full-text\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;15\\\/12\\\/5\u0022},{\u0022requested\u0022:\u0022long\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;15\\\/12\\\/5\u0022}],\u0022ac\u0022:{\u0022spmdc;15\\\/12\\\/5\u0022:{\u0022access\u0022:{\u0022reprint\u0022:true,\u0022full\u0022:true},\u0022pisa_id\u0022:\u0022spmdc;15\\\/12\\\/5\u0022,\u0022atom_uri\u0022:\u0022\u0022,\u0022jcode\u0022:\u0022spmdc\u0022}}},\u0022googleanalytics\u0022:{\u0022trackOutbound\u0022:1,\u0022trackMailto\u0022:1,\u0022trackDownload\u0022:1,\u0022trackDownloadExtensions\u0022:\u00227z|aac|arc|arj|asf|asx|avi|bin|csv|doc(x|m)?|dot(x|m)?|exe|flv|gif|gz|gzip|hqx|jar|jpe?g|js|mp(2|3|4|e?g)|mov(ie)?|msi|msp|pdf|phps|png|ppt(x|m)?|pot(x|m)?|pps(x|m)?|ppam|sld(x|m)?|thmx|qtm?|ra(m|r)?|sea|sit|tar|tgz|torrent|txt|wav|wma|wmv|wpd|xls(x|m|b)?|xlt(x|m)|xlam|xml|z|zip\u0022,\u0022trackUrlFragments\u0022:1},\u0022ajaxPageState\u0022:{\u0022js\u0022:{\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/jquery.cluetip.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.hoverIntent.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.bgiframe.min.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_at_symbol.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_article_reference_popup.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/contrib\\\/google_analytics\\\/googleanalytics.js\u0022:1,\u00220\u0022:1}}});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/advagg_css\/css__ce2QY63WIanKyr8eSq7eavr1XQRRmFD6ZSmwpyJi8lM__zXwFqpqmxrZOXXcd_TpBQpjuELbmIP9wBR5UuTDWAO4__YJWWMMdfCJuAFm5cUEp88OsodhO3ZA-2lzRfoBsSlk4.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink rel=\u0027stylesheet\u0027 type=\u0027text\/css\u0027 href=\u0027\/sites\/all\/modules\/contrib\/panels\/plugins\/layouts\/onecol\/onecol.css\u0027 \/\u003E\u003C\/head\u003E\u003Cbody\u003E\u003Cdiv class=\u0022panels-ajax-tab-panel panels-ajax-tab-panel-sageoa-tab-art\u0022\u003E\u003Cdiv class=\u0022panel-display panel-1col clearfix\u0022 \u003E\n  \u003Cdiv class=\u0022panel-panel panel-col\u0022\u003E\n    \u003Cdiv\u003E\u003Cdiv class=\u0022panel-pane pane-highwire-markup\u0022 \u003E\n  \n      \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv class=\u0022highwire-markup\u0022\u003E\u003Cdiv xmlns=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022 id=\u0022content-block-markup\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cdiv class=\u0022article fulltext-view \u0022\u003E\u003Cspan class=\u0022highwire-journal-article-marker-start\u0022\u003E\u003C\/span\u003E\u003Cdiv class=\u0022section abstract\u0022 id=\u0022abstract-1\u0022\u003E\u003Ch2\u003ESummary\u003C\/h2\u003E\u003Cp id=\u0022p-1\u0022\u003ETwo new implantable cardioverter defibrillator systems developed for compatibility with magnetic resonance imaging demonstrate safety and efficacy in the Evera MRI and ProMRI trials, with no significant changes in ventricular pacing threshold \u0026lt;\u20055.0 V or ventricular sensing. In addition, there were no serious device-related events in both studies.\u003C\/p\u003E\u003C\/div\u003E\u003Cul class=\u0022kwd-group\u0022\u003E\u003Cli class=\u0022kwd\u0022\u003Eimplantable cardioverter defibrillators\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003EICD\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Eventricular pacing\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003EMRI\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003EEvera MRI\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003EProMRI\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003ENCT02117414\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003ENCT02096692\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Ecardiology \u0026amp; cardiovascular medicine clinical trials\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Eimaging modalities\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Einterventional techniques \u0026amp; devices\u003C\/li\u003E\u003C\/ul\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-1\u0022\u003E\u003Cp id=\u0022p-2\u0022\u003ETwo new implantable cardioverter defibrillators (ICDs) have been demonstrated to be safe and effective in magnetic resonance imaging (MRI) scanning conditions. Michael R. Gold, MD, PhD, Medical University of South Carolina, Charleston, South Carolina, USA, presented data from the Evera MRI study [Gold MR et al. \u003Cem\u003EJ Am Coll Cardiol\u003C\/em\u003E. 2015], and Khaled A. Awad, MD, University of Alabama Birmingham School of Medicine, Birmingham, Alabama, USA, presented data from the ProMRI study [\u003Ca class=\u0022external-ref external-ref-type-clintrialgov\u0022 href=\u0022\/lookup\/external-ref?link_type=CLINTRIALGOV\u0026amp;access_num=NCT02096692\u0026amp;atom=%2Fspmdc%2F15%2F12%2F5.atom\u0022\u003ENCT02096692\u003C\/a\u003E].\u003C\/p\u003E\u003Cp id=\u0022p-3\u0022\u003EDue to the risks associated with devices during imaging, MRI is contraindicated in many patients with ICDs. Although MRI-safe pacemakers are available, there are currently no MRI-safe ICDs approved by the FDA. MRI has been used in some ICD patients in select centers; however, limitations must be imposed, such as restriction of imaging to particular body areas. The purpose of the Evera MRI and ProMRI studies was to evaluate the safety and efficacy of new ICD systems that were developed to be MRI compatible.\u003C\/p\u003E\u003Cp id=\u0022p-4\u0022\u003EIn the international open-label prospective Evera MRI study, 263 patients who had successful ICD implantation were randomly assigned 2:1 to undergo MRI scans of the chest, spine, and head or to enter a waiting period. Patients in the MRI arm received clinically relevant scans with a maximized gradient slew rate, a whole body \u0026lt;\u20052.0 W\/kg with 20 minutes of active scan duration, and 50 minutes in the MRI bore.\u003C\/p\u003E\u003Cp id=\u0022p-5\u0022\u003EThe primary efficacy end points were ventricular pacing capture threshold (\u0026gt;\u20050.5 V) and ventricular sensing (\u0026gt;\u200550% decrease). The primary safety end points included complications related to the MRI, loss of capture, and treated ventricular arrhythmias during the scan. Success was defined as achievement of all 3 end points. Patients were excluded if they required device upgrades, change-outs, lead extractions, or lead or device revisions or if they had abandoned or capped leads or a non-MRI-compatible device or material implant.\u003C\/p\u003E\u003Cp id=\u0022p-6\u0022\u003EThe change in ventricular pacing capture threshold was noninferior between the 2 arms, with 100% and 98.8% success rates in the MRI and control arms, respectively (\u003Cem\u003EP\u003C\/em\u003E\u003Csub\u003ENoninferiority\u003C\/sub\u003E\u2005\u0026lt;\u2005.0001; \u003Ca id=\u0022xref-fig-1-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F1\u0022\u003EFigure 1\u003C\/a\u003E). In addition, there was no difference in ventricular sensing amplitude at 1 month post-MRI compared with patients who underwent a waiting period, with success achieved by 99.3% and 98.8% in the MRI and control arms, respectively (\u003Cem\u003EP\u003C\/em\u003E\u003Csub\u003ENoninferiority\u003C\/sub\u003E\u2005=\u2005.0001). The MRI arm achieved noninferiority for the secondary end points, including atrial pacing capture threshold, atrial sensing amplitude, right ventricular defibrillation impedance, and system-related complication-free rate \u0026gt;\u200580%.\u003C\/p\u003E\u003Cdiv id=\u0022F1\u0022 class=\u0022fig pos-float  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/15\/12\/5\/F1.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Change in Ventricular Pacing Capture Threshold in the Evera MRI StudyMRI, magnetic resonance imaging.Reproduced with permission from MR Gold, MD, PhD.\u0022 class=\u0022fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-837990962\u0022 data-figure-caption=\u0022Change in Ventricular Pacing Capture Threshold in the Evera MRI StudyMRI, magnetic resonance imaging.Reproduced with permission from MR Gold, MD, PhD.\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cimg class=\u0022fragment-image\u0022 alt=\u0022Figure 1.\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/15\/12\/5\/F1.medium.gif\u0022\/\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u00220 first\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/15\/12\/5\/F1.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 1.\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00221\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/15\/12\/5\/F1.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00222 last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/16716\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 1.\u003C\/span\u003E \u003Cp id=\u0022p-7\u0022 class=\u0022first-child\u0022\u003EChange in Ventricular Pacing Capture Threshold in the Evera MRI Study\u003C\/p\u003E\u003Cp id=\u0022p-8\u0022\u003EMRI, magnetic resonance imaging.\u003C\/p\u003E\u003Cp id=\u0022p-9\u0022\u003EReproduced with permission from MR Gold, MD, PhD.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-10\u0022\u003EThe complication-free rate was 100% among all 147 patients who underwent MRI; however, 2 patients experienced implant site warmth, and 1 patient each experienced atrial tachycardia, back pain, and burning sensation of the forehead.\u003C\/p\u003E\u003Cp id=\u0022p-11\u0022\u003EIn the multicenter prospective nonrandomized single-arm ProMRI study, 154 patients received the Iforia ProMRI ICD system and underwent a thoracic spine or cardiac 1.5T closed-bore MRI. In addition, the maximum slew rate was \u2264\u2005200 T\/ms per axis, and the specific absorption rate was up to 2.0 W\/kg for the entire body and 3.2 W\/kg for the head. Patients were excluded from the study if they had planned cardiac surgery within 3 months, had a life expectancy \u0026lt;\u20053 months, had an abandoned ICD or pacemaker leads, were pregnant, or had any prostheses or devices that were non-MRI compatible. The end points of the ProMRI study included freedom from the following: serious adverse device events, ventricular capture threshold increase, and decrease in ventricular sensing.\u003C\/p\u003E\u003Cp id=\u0022p-12\u0022\u003EFreedom from ventricular capture threshold \u0026gt;\u20050.5 V was achieved by 100% of patients (n\u2005=\u2005153), with most patients experiencing no change in voltage (\u003Cem\u003EP\u003C\/em\u003E\u2005\u0026lt;\u2005.001). Similarly, the freedom from decrease in ventricular sensing was achieved by 99.3% of patients at 1 month (\u003Cem\u003EP\u003C\/em\u003E\u2005\u0026lt;\u2005.001). In addition, there were no significant changes in P wave amplitude, atrial pacing threshold, right ventricular pacing impedance, shock impedance, and batter capacity after MRI. In the study, 43 adverse events occurred that were deemed not related to the device; therefore, there were no serious adverse device events.\u003C\/p\u003E\u003Cp id=\u0022p-13\u0022\u003EIn conclusion, Dr Gold and Dr Awad indicated that the data from the Evera MRI and ProMRI studies demonstrated that the Evera MRI and Iforia ICD systems, respectively, were safe and effective in patients undergoing MRI, with no difference in pacing or sensing detected.\u003C\/p\u003E\u003C\/div\u003E\u003Cul class=\u0022copyright-statement\u0022\u003E\u003Cli class=\u0022fn\u0022 id=\u0022copyright-statement-1\u0022\u003E\u00a9 2015 SAGE Publications\u003C\/li\u003E\u003C\/ul\u003E\u003Cspan class=\u0022highwire-journal-article-marker-end\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Cspan id=\u0022related-urls\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Ca href=\u0022http:\/\/mdc.sagepub.com\/content\/15\/12\/5.abstract\u0022 class=\u0022hw-link hw-link-article-abstract\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView Summary\u003C\/a\u003E\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E\n\u003C\/div\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_figures.js?nzlj21\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_openurl.js?nzlj21\u0022\u003E\u003C\/script\u003E\n\u003C\/body\u003E\u003C\/html\u003E"}